Refractory Asthma Stratification Programme (RASP-UK)
Updated: Feb 21
New Asthma Research Study: RASP-UK
The RASP-UK Consortium is a large scale research project that aims to target treatments effectively in patients with severe asthma.
Difficult to treat asthma affects up to 20% of patients with asthma in the UK despite currently available therapies and is associated with significant healthcare cost. Treatment guidelines advise the ‘step wise’ increase of corticosteroids but the response is often poor as this “one size fits all” approach does not benefit all patients. Characterising a patient’s response to treatment will help our understanding of non-response and will aid development of new drugs for severe asthma.
The RASP-UK Consortium brings together a partnership of clinical and academic excellence from UK Universities and NHS Severe Asthma Centres, together with the Pharmaceutical Industry. The primary focus is to target corticosteroid treatments more effectively and to understand why some patients do not respond to corticosteroids.
For more information: